Open AccessMicroRNA‑2682‑3p inhibits osteosarcoma cell proliferation by targeting CCND2, MMP8 and Myd88
Author(s) -
Fan Zhang,
Yanjie Zhu,
Guoxin Fan,
Shuo Hu
Publication year - 2018
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2018.9029
Subject(s) - osteosarcoma , cancer research , cell cycle , microrna , cyclin d1 , oncogene , cell growth , downregulation and upregulation , cell cycle checkpoint , medicine , biology , cancer , gene , genetics
Osteosarcoma is the most common primary bone malignancy in children and young adults. It is associated with dysregulation of certain microRNAs (miRNAs/miRs), which provides a target for osteosarcoma therapy. miR-2682-3p expression in osteosarcoma cell lines and tissues was assayed by reverse transcription-quantitative polymerase chain reaction and was upregulated or downregulated by transfection with miRNA mimics or inhibitors. miR-2682-3p was downregulated in osteosarcoma tissues and cell lines, and overexpression of miR-2682-3p inhibited tumor growth. Further studies revealed that cyclin D1 (CCND)2 , matrix metalloproteinase (MMP)8 , and myeloid differentiation primary response (Myd)88 were the direct targets of miR-2682-3p in osteosarcoma cells. Overexpression of miR-2682-3p promoted osteosarcoma cell apoptosis by targeting CCND2, MMP8 , and Myd88 , and vice-versa. Therefore, miR-2682-3p may act as a tumor suppressor gene, the downregulation of which contributed to the progression and metastasis of osteosarcoma, to provide a potential therapy target for patients with osteosarcoma.